TARA (STOCKS)
Protara Therapeutics, Inc. Common Stock
$5.040000
+0.080000 (+1.61%)
Prev close: $4.960000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Jesse Shefferman
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $273.94M
- Employees
- 33
- P/E (TTM)
- -3.79
- P/B (TTM)
- 1.38
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
10
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.37 | $-0.33 | -0.0385 | -11.61% |
|
Sep 2025 (Q3)
|
$-0.31 | $-0.39 | +0.0817 | +20.86% |
|
Jun 2025 (Q2)
|
$-0.35 | $-0.41 | +0.0631 | +15.27% |
|
Mar 2025 (Q1)
|
$-0.29 | $-0.46 | +0.1710 | +37.09% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $7.11M |
| Operating Expenses | $64.55M |
| Research and Development | $42.63M |
| Other Operating Expenses | $21.92M |
| Operating Income/Loss | -$64.55M |
| Income/Loss From Continuing Operations After Tax | $68.39M |
| Income/Loss From Continuing Operations Before Tax | $57.35M |
| Income Tax Expense/Benefit | -$11.04M |
| Income Tax Expense/Benefit, Deferred | -$11.04M |
| Net Income/Loss | -$57.44M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$57.44M |
| Net Income/Loss Available To Common Stockholders, Basic | -$57.44M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.34 |
| Diluted Earnings Per Share | -$1.34 |
| Basic Average Shares | 42,836,129 |
| Diluted Average Shares | 42,836,129 |
| Assets | $209.47M |
| Current Assets | $159.50M |
| Noncurrent Assets | $49.96M |
| Fixed Assets | $759.00K |
| Other Non-current Assets | $49.21M |
| Liabilities | $13.06M |
| Current Liabilities | $10.94M |
| Accounts Payable | $3.47M |
| Wages | $3.27M |
| Other Current Liabilities | $4.20M |
| Noncurrent Liabilities | $2.12M |
| Equity | $196.41M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $196.41M |
| Liabilities And Equity | $209.47M |
| Net Cash Flow From Operating Activities | -$56.37M |
| Net Cash Flow From Operating Activities, Continuing | -$56.37M |
| Net Cash Flow From Investing Activities | -$139.49M |
| Net Cash Flow From Investing Activities, Continuing | -$139.49M |
| Net Cash Flow From Financing Activities | $82.72M |
| Net Cash Flow From Financing Activities, Continuing | $82.72M |
| Net Cash Flow | -$113.14M |
| Net Cash Flow, Continuing | -$113.14M |
| Comprehensive Income/Loss | -$57.35M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$57.35M |
| Other Comprehensive Income/Loss | $88.00K |